Doug Besch - Net Worth and Insider Trading

Doug Besch Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Doug Besch owns 1 companies in total, including OptimizeRx Corp (OPRX) .

Click here to see the complete history of Doug Besch’s form 4 insider trades.

Insider Ownership Summary of Doug Besch

Ticker Comapny Transaction Date Type of Owner
OPRX OptimizeRx Corp 2022-10-01 Chief Product Officer

Doug Besch Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Doug Besch Ownership Network

Ownership Network List of Doug Besch

No Data

Ownership Network Relation of Doug Besch


Doug Besch Owned Company Details

What does OptimizeRx Corp do?

Who are the key executives at OptimizeRx Corp?

Doug Besch is the Chief Product Officer of OptimizeRx Corp. Other key executives at OptimizeRx Corp include General Counsel and CCO Marion Odence-ford , Chief Commercial Officer Theresa Greco , and Chief Executive Officer William J Febbo .

OptimizeRx Corp (OPRX) Insider Trades Summary

Over the past 18 months, Doug Besch made no insider transaction in OptimizeRx Corp (OPRX). Other recent insider transactions involving OptimizeRx Corp (OPRX) include a net sale of 4,000 shares made by Marion Odence-ford ,

In summary, during the past 3 months, insiders sold 0 shares of OptimizeRx Corp (OPRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 4,000 shares of OptimizeRx Corp (OPRX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 4,000 shares.

OptimizeRx Corp (OPRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

OptimizeRx Corp Insider Transactions

No Available Data

Doug Besch Mailing Address

Above is the net worth, insider trading, and ownership report for Doug Besch. You might contact Doug Besch via mailing address: 400 Water Street, Suite 200, Rochester Mi 48307.

Discussions on Doug Besch

No discussions yet.